{"id":88102,"date":"2026-05-17T03:16:07","date_gmt":"2026-05-17T03:16:07","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/88102\/"},"modified":"2026-05-17T03:16:07","modified_gmt":"2026-05-17T03:16:07","slug":"evropa-chce-leky-zpatky-na-kontinetu-cesi-z-toho-budou-profitovat","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/88102\/","title":{"rendered":"Evropa chce l\u00e9ky zp\u00e1tky na kontinetu. \u010ce\u0161i z toho budou profitovat"},"content":{"rendered":"

\u010cesk\u00fd farmaceutick\u00fd<\/a> byznys za\u017e\u00edv\u00e1 v\u00a0posledn\u00edch letech boom<\/a>. Ukazuje na to srovn\u00e1n\u00ed studi\u00ed Deloitte z\u00a0let 2020 a\u00a02026. Nav\u00edc se schyluje k\u00a0dal\u0161\u00edmu r\u016fstu. \u010cesko coby v\u00fdrobce generick\u00fdch l\u00e9k\u016f, tedy t\u011bch, jim\u017e vypr\u0161ela patentov\u00e1 p\u0159ihl\u00e1\u0161ka, bude profitovat z\u00a0glob\u00e1ln\u00edho p\u0159esunu v\u00fdroby z\u00a0asijsk\u00fdch zem\u00ed, k\u00a0n\u011bmu\u017e zavelela Evropsk\u00e1 unie. M\u00e1 zamezit v\u00fdpadk\u016fm l\u00e9k\u016f, jak\u00e9 \u010cesko i\u00a0dal\u0161\u00ed zem\u011b za\u017eily v\u00a0posledn\u00edch letech opakovan\u011b.<\/p>\n

P\u0159elom let 2022 a\u00a02023<\/a> byl ve znamen\u00ed dosud nejv\u00fdrazn\u011bj\u0161\u00edch v\u00fdpadk\u016f<\/a> za posledn\u00edch t\u0159icet let. V\u00a0l\u00e9k\u00e1rn\u00e1ch dlouhodob\u011b chyb\u011bly sirupy s\u00a0obsahem ibuprofenu pro d\u011bti, na za\u010d\u00e1tku roku 2023 chyb\u011bl t\u00e9m\u011b\u0159 cel\u00fd sortiment z\u00e1kladn\u00edch antibiotik.<\/p>\n

\"Zapla\u0165te<\/a>Zapla\u0165te za zne\u010di\u0161t\u011bn\u00ed \u0159ek, \u0159\u00edk\u00e1 EU farmaceutick\u00fdm firm\u00e1m. Zentiva podala \u017ealobu a \u010dek\u00e1 zdra\u017een\u00ed l\u00e9k\u016f<\/a><\/p>\n

Nejde p\u0159itom o\u00a0\u017e\u00e1dn\u00e1 specifick\u00e1 l\u00e9\u010diva, ale o\u00a0generika. Jejich v\u00fdrobu velk\u00e9 firmy p\u0159esunuly do zem\u00ed s\u00a0ni\u017e\u0161\u00edmi n\u00e1klady na v\u00fdrobu, typicky do \u010c\u00edny nebo Indie. Evropa je nyn\u00ed l\u00e1k\u00e1 pr\u00e1v\u011b kv\u016fli opakovan\u00fdm nedostatk\u016fm zp\u011bt.<\/p>\n

A t\u011b\u017eit z toho m\u016f\u017ee i\u00a0\u010cesko, jeden z\u00a0pomysln\u00fdch generick\u00fdch ostr\u016fvk\u016f Evropy. Podle OECD pat\u0159\u00ed v\u00a0generik\u00e1ch zem\u011b mezi st\u0159edn\u011b siln\u00e9 hr\u00e1\u010de. Na N\u011bmecko \u010di It\u00e1lii ztr\u00e1c\u00ed sice dost, v\u00a0p\u0159epo\u010dtu na obyvatele se d\u00e1 ale \u010desk\u00e1 produkce za v\u00fdznamnou pova\u017eovat. \u010c\u00edsly farmaceutick\u00e9ho byznysu \u0159e\u010deno: V\u00a0zemi p\u016fsob\u00ed p\u0159ibli\u017en\u011b 150\u00a0v\u00fdrobc\u016f a\u00a0kontroln\u00edch laborato\u0159\u00ed, p\u0159i\u010dem\u017e sektor je v\u00fdznamn\u011b orientov\u00e1n pr\u00e1v\u011b na generickou v\u00fdrobu, a\u00a0to ze 78\u00a0procent.<\/p>\n

\u00da\u0159edn\u00edci i\u00a0politici se shodli<\/p>\n

Rada a\u00a0parlament EU v\u00a0posledn\u00edch dnech na\u0161ly p\u0159edb\u011b\u017en\u00fd kompromis na tom, jak v\u00fdpadky l\u00e9k\u016f nap\u0159\u00ed\u0161t\u011b zastavit. C\u00edlem je podpora p\u0159esunu vyjmenovan\u00fdch l\u00e9k\u016f a\u00a0l\u00e1tek zp\u011bt na kontinent. M\u00e1 j\u00edt o\u00a0antibiotika, l\u00e9\u010diva pro urgentn\u00ed medic\u00ednu, na kardiovaskul\u00e1rn\u00ed onemocn\u011bn\u00ed, pro diabetiky a\u00a0o\u00a0vybran\u00e9 z\u00e1kladn\u00ed onkologick\u00e9 l\u00e9ky a\u00a0podobn\u011b.<\/p>\n

Podpory se maj\u00ed do\u010dkat v\u00fdrobci t\u0159eba t\u00edm, \u017ee jejich odb\u011bratel\u00e9 nebudou muset vyb\u00edrat podle nejni\u017e\u0161\u00ed ceny, ale v\u00a0tendrech dostanou dovolen\u00ed zohlednit pr\u00e1v\u011b i\u00a0bezpe\u010dnost dod\u00e1vek, tedy dom\u00e1c\u00ed a\u00a0teoreticky dra\u017e\u0161\u00ed produkci. \u201eDal\u0161\u00edm pozitivem je nap\u0159\u00edklad jednodu\u0161\u0161\u00ed zp\u016fsob povolovac\u00edch proces\u016f p\u0159i registraci l\u00e9\u010div \u010di snadn\u011bj\u0161\u00ed povolov\u00e1n\u00ed staveb pro v\u00fdrobu l\u00e9\u010div, \u00fazemn\u00ed \u0159\u00edzen\u00ed a\u00a0jin\u00e9. Oce\u0148ujeme i\u00a0mo\u017enost z\u00edskat na roz\u0161i\u0159ov\u00e1n\u00ed v\u00fdrobn\u00edch kapacit finan\u010dn\u00ed prost\u0159edky z\u00a0n\u00e1rodn\u00edch nebo evropsk\u00fdch fond\u016f,\u201c \u0159\u00edk\u00e1 Filip Vrubel, v\u00fdkonn\u00fd \u0159editele \u010cesk\u00e9 asociace farmaceutick\u00fdch firem (\u010cAFF).<\/p>\n

\"L\u00e9ky<\/a>L\u00e9ky na obezitu m\u011bn\u00ed ekonomiku a mohou pos\u00edlit udr\u017eitelnost ve\u0159ejn\u00e9ho zdravotnictv\u00ed <\/a><\/p>\n

K p\u0159esunu<\/a> v\u00fdroby z\u00a0Asie se producenti sami podle n\u011bj dosud neodhodlali. \u201eJe to komplikovan\u00fd proces, kter\u00fd trv\u00e1 n\u011bkolik let. Naopak vid\u00edme \u010d\u00e1ste\u010dnou snahu p\u0159esunout \u010d\u00e1st v\u00fdroby do USA, a\u00a0to kv\u016fli politice B\u00edl\u00e9ho domu zam\u011b\u0159en\u00e9 zejm\u00e9na na dra\u017e\u0161\u00ed, inovativn\u00ed l\u00e9ky. I\u00a0na tom lze pozorovat, \u017ee bez siln\u00fdch opat\u0159en\u00ed vl\u00e1d nelze doufat v\u00a0pos\u00edlen\u00ed odolnosti dodavatelsk\u00fdch \u0159et\u011bzc\u016f,\u201c popisuje d\u00e1le Vrubel.<\/p>\n

\u010cesk\u00fd farmabyznys zm\u011bny vyhl\u00ed\u017e\u00ed s\u00a0rekordn\u00edm r\u016fstem v\u00a0z\u00e1dech, jak ukazuj\u00ed \u010derstv\u00e1 \u010d\u00edsla. Chystan\u00e9 evropsk\u00e9 zm\u011bny ho mohou jednozna\u010dn\u011b je\u0161t\u011b v\u00edce pos\u00edlit. \u201eM\u00e1me zde rychle rostouc\u00ed farmaceutick\u00fd sektor, kter\u00fd m\u00e1 z\u00a0pohledu budouc\u00ed konkurenceschopnosti mimo\u0159\u00e1dn\u00fd v\u00fdznam. Ka\u017ed\u00e1 koruna utracen\u00e1 v\u00a0tomto odv\u011btv\u00ed vygeneruje 2,1n\u00e1sobek,\u201c \u0159\u00edk\u00e1 David Marek, hlavn\u00ed ekonom spole\u010dnosti Deloitte.<\/p>\n

Tr\u017eby rostou<\/p>\n

Na farmaceutick\u00fd pr\u016fmysl je v\u00a0\u010cesku nav\u00e1z\u00e1no asi 39\u00a0300\u00a0pracovn\u00edch m\u00edst, nap\u0159\u00edmo pr\u016fmysl zam\u011bstn\u00e1v\u00e1 necel\u00fdch 13\u00a0500\u00a0osob. Na fakt, \u017ee tuzemsk\u00e1 ekonomika st\u00e1le v\u00edce profituje ze sv\u00e9ho farmaceutick\u00e9ho byznysu, ukazuj\u00ed dv\u011b studie spole\u010dnosti Deliotte. Prvn\u00ed vznikla pro \u010ceskou asociaci farmaceutick\u00fdch firem v\u00a0roce 2020, druh\u00e1 p\u0159ed p\u00e1r t\u00fddny pro Svaz pr\u016fmyslu a\u00a0dopravy \u010cR. Zdaleka ne v\u0161echna data jsou srovnateln\u00e1, dva kl\u00ed\u010dov\u00e9 \u00fadaje ale ano.<\/p>\n

Jde o dopad na tr\u017eby firem ve v\u0161ech ostatn\u00edch odv\u011btv\u00edch. A\u00a0ten \u010dinil podle \u00fadaj\u016f z\u00a0roku 2020 zhruba 97\u00a0miliard korun, podle leto\u0161n\u00edch \u010d\u00edsel to bylo u\u017e p\u0159ibli\u017en\u011b 153\u00a0miliard. Hrub\u00e1 p\u0159idan\u00e1 hodnota v\u00fdrobn\u00edho farmaceutick\u00e9ho pr\u016fmyslu pak stoupla z\u00a021 na 63\u00a0miliard. \u201eFarmaceutick\u00fd sektor ukazuje, \u017ee investice do v\u00fdzkumu, inovac\u00ed a\u00a0do lid\u00ed nejsou n\u00e1kladem, ale dlouhodobou investic\u00ed s\u00a0vysokou n\u00e1vratnost\u00ed pro celou ekonomiku. Je to skv\u011bl\u00fd p\u0159\u00edklad druh\u00e9 ekonomick\u00e9 transformace z\u00a0v\u00fdrobn\u00ed na ekonomiku s\u00a0vysokou p\u0159idanou hodnotou,\u201c komentoval v\u00fdvoj Tom\u00e1\u0161 Kol\u00e1\u0159, \u010dlen p\u0159edstavenstva Svazu pr\u016fmyslu a\u00a0dopravy \u010cR.<\/p>\n","protected":false},"excerpt":{"rendered":"\u010cesk\u00fd farmaceutick\u00fd byznys za\u017e\u00edv\u00e1 v\u00a0posledn\u00edch letech boom. Ukazuje na to srovn\u00e1n\u00ed studi\u00ed Deloitte z\u00a0let 2020 a\u00a02026. Nav\u00edc se…\n","protected":false},"author":2,"featured_media":88103,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3],"tags":[27255,68,27254,42,7602,708,109,108,106,27253,1617,592,2132],"class_list":["post-88102","post","type-post","status-publish","format-standard","has-post-thumbnail","category-evropa","tag-antibiotikum","tag-byznys","tag-ceska-asociace-farmaceutickych-firem","tag-cesko","tag-deloitte","tag-ekonomika","tag-europa","tag-europe","tag-evropa","tag-lecivo","tag-leky","tag-prumysl","tag-vyroba"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116587750177700422","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/88102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=88102"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/88102\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/88103"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=88102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=88102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=88102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}